Loading market dashboard
Mustang Bio, Inc.
MBIOHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Vancouver, British Columbia – April 1, 2026 – TheNewswire - MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce that it has closed its previously announced upsized non-brokered private placement (the “ Offering ”) for gross proceeds of $1,437,828.87
Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “ Offering ”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units of the Company (the “ Units ”) at a price of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit will consist of one common share of the Company (each, a “ Share ”) and one Share purchase warrant (each, a “ Warrant ”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.
